HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel frame-shift mutation in Slc5a2 encoding SGLT2 in a strain of senescence-accelerated mouse SAMP10.

Abstract
The senescence-accelerated mouse prone10 (SAMP10) strain, a model of aging, exhibits cognitive impairments and cerebral atrophy. We noticed that SAMP10/TaSlc mice, a SAMP10 substrain, have developed persistent glucosuria over the past few years. In the present study, we characterized SAMP10/TaSlc mice and further identified a spontaneous mutation in the Slc5a2 gene encoding sodium-glucose co-transporter (SGLT) 2. The mean concentration of urine glucose was high in SAMP10/TaSlc mice and increased further with advancing age, whereas other strains of senescence-accelerated mice, including SAMP1/SkuSlc, SAMP6/TaSlc and SAMP8/TaSlc or normal aging control SAMR1/TaSlc mice, exhibited no detectable glucose in urine. SAMP10/TaSlc mice consumed increasing amounts of food and water compared to SAMR1/TaSlc mice, suggesting the compensation of polyuria and the loss of glucose. Oral glucose tolerance tests showed decreased glucose reabsorption in the kidney of SAMP10/TaSlc mice. In addition, blood glucose levels decreased in an age-dependent fashion. The kidney was innately larger than that of control mice with no histological alterations. We examined the expression levels of glucose transporters in the kidney. Among SGLT1, SGLT2, glucose transporter (GLUT) 1 and GLUT2, we found a significant decrease only in the level of SGLT2. DNA sequencing of SGLT2 in SAMP10/TaSlc mice revealed a single nucleotide deletion of guanine at 1236, which resulted in a frameshift mutation that produced a truncated protein. We designate this strain as SAMP10/TaSlc-Slc5a2(slc) (SAMP10-ΔSglt2). Recently, SGLT2 inhibitors have been demonstrated to be effective for the treatment of patients with type 2 diabetes (T2D). SAMP10-ΔSglt2 mice may serve as a unique preclinical model to study the link between aging-related neurodegenerative disorders and T2D.
AuthorsKeiko Unno, Hiroyuki Yamamoto, Masateru Toda, Shiori Hagiwara, Kazuaki Iguchi, Minoru Hoshino, Fumiyo Takabayashi, Sanae Hasegawa-Ishii, Atsuyoshi Shimada, Masanori Hosokawa, Keiichi Higuchi, Masayuki Mori
JournalBiochemical and biophysical research communications (Biochem Biophys Res Commun) Vol. 454 Issue 1 Pg. 89-94 (Nov 07 2014) ISSN: 1090-2104 [Electronic] United States
PMID25450362 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Inc. All rights reserved.
Chemical References
  • Blood Glucose
  • Codon, Terminator
  • Glucose Transporter Type 1
  • Glucose Transporter Type 2
  • Mutant Proteins
  • RNA, Messenger
  • Slc2a1 protein, mouse
  • Slc2a2 protein, mouse
  • Slc5a1 protein, mouse
  • Slc5a2 protein, mouse
  • Sodium-Glucose Transporter 1
  • Sodium-Glucose Transporter 2
Topics
  • Aging (genetics, metabolism)
  • Aging, Premature (genetics, metabolism)
  • Amino Acid Sequence
  • Animals
  • Base Sequence
  • Blood Glucose (metabolism)
  • Codon, Terminator (genetics)
  • Diabetes Mellitus, Type 2 (genetics, metabolism)
  • Disease Models, Animal
  • Frameshift Mutation
  • Glucose Transporter Type 1 (genetics, metabolism)
  • Glucose Transporter Type 2 (genetics, metabolism)
  • Humans
  • Kidney (metabolism)
  • Male
  • Mice
  • Mice, Mutant Strains
  • Molecular Sequence Data
  • Mutant Proteins (chemistry, genetics, metabolism)
  • Neurodegenerative Diseases (genetics, metabolism)
  • RNA, Messenger (genetics, metabolism)
  • Sodium-Glucose Transporter 1 (genetics, metabolism)
  • Sodium-Glucose Transporter 2 (chemistry, genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: